Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Licenses Canadian Rights to miRNA Diagnostics to Warnex

Premium

Rosetta Genomics said this week that it has signed a deal making Warnex Medical Laboratories the exclusive distributor of Rosetta's three microRNA-based diagnostics in Canada.

Under the deal, Warnex will market Rosetta's miRview Meso, which differentiates lung cancer from mesothelioma; miRview Mets, which is designed to determine the source of cancers of unknown primary origin; and miRview Squamous, which is designed to differentiate squamous from non-squamous non-small cell lung cancer.

The company will send tissue samples from its Canadian customers to Rosetta's Philadelphia-based lab for analysis.

Additional terms of the deal were not disclosed.

Rosetta has long been on the lookout for marketing partners for its miRNA tests. In April, it signed a deal giving Prometheus Laboratories the US rights to the three diagnostics (see RNAi News, 4/16/2009). In January, it licensed the Israeli and Turkish rights to Teva Pharmaceuticals (see RNAi News, 1/8/2009).

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.